To examine cancer - specific stress at treatment initiation as a predictor of psychological and physical functioning trajectories in patients with relapsed / refractory chronic
lymphocytic leukemia during the first 5 months of treatment.
Not exact matches
Venetoclax has durable clinical activity in patients with relapsed / refractory chronic
lymphocytic leukemia whose disease progressed
during or after ibrutinib therapy.
Among patients with relapsed / refractory chronic
lymphocytic leukemia, those who have higher stress related to their cancer experience at the start of treatment have worse psychological functioning
during the first five months of treatment.
Findings suggest cancer - specific stress at treatment initiation may be a risk factor for poorer psychological functioning
during treatment for patients with relapsed / refractory chronic
lymphocytic leukemia.